Aralez Bio specializes in the development and production of noncanonical amino acids, which are essential building blocks for next-generation therapeutics. Their innovative enzyme platform allows for the efficient and sustainable synthesis of these amino acids, significantly reducing production costs and lead times compared to traditional methods. By leveraging biocatalysis and protein engineering, Aralez Bio can produce a diverse array of amino acids, including tryptophan and tyrosine analogs, which are critical for optimizing drug properties such as efficacy, specificity, and bioavailability. This technology not only enhances the drug discovery process but also supports the creation of a wide range of products across various industries.

The company's approach to amino acid production emphasizes sustainability and scalability, utilizing low-cost starting materials and generating less waste. Aralez Bio's platform has established the largest collection of tryptophan analogs globally, enabling researchers to access a vast library of compounds quickly. This capability is particularly beneficial for pharmaceutical companies looking to accelerate their research and development timelines. By focusing on noncanonical amino acids, Aralez Bio aims to unlock new chemical design spaces, fostering innovation in drug development and other applications, ultimately contributing to a greener and more efficient future in biotechnology.

United States

We have invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Our proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, with water as the only byproduct.  To learn more, visit us at www.aralezbio.com

Aralez Bio is a proud member of Cyclotron Road.

Aralez Bio

Company Details